Conclusions
dementia, MCI, cognitive impairment
SECONDARY
This secondary analysis of the SPRINT randomized clinical trial found that participants with higher baseline risk of MCI or dementia gained the greatest absolute benefit from intensive SBP treatment. The baseline clinical factors associated with risk of MCI or dementia include older age, worse kidney function, being enrolled in Medicare or Veterans Health Administration insurance, lower educational attainment, and low baseline cognitive function. If we are to prioritize intensifying antihypertensive treatment based on cognitive benefit, especially among patients who lack equitable access to health care and in resource-poor settings, we would recommend targeting patients at high risk of cognitive impairment initially. However, we had limited ability in identifying benefit in patients with high cognitive risk at baseline due to limited sample size.